Dynavax regains full tights to investigational TLR 7/9 inhibitor DV1179
Dynavax announced it has regained full rights to DV1179, an investigational bifunctional inhibitor of toll-like receptors 7 and 9. This resulted from the expiration of the R&D Collaboration and License Agreement with GSK originally executed in 2008. November 28, 2014